IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
NEW YORK, Oct. 03, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced three poster presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023), to be held in San Diego, California on November 1-5, 2023. Two of the posters will include new in vivo and in vitro data related to IO Biotech’s lead therapeutic cancer vaccine candidate, IO102-IO103, currently being evaluated in a pivotal Phase 3 study. The third poster contains new pre-clinical data for the next candidate in the IO Biotech pipeline, IO112, which targets Arginase 1.
